NO20041186L - Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav - Google Patents
Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser deravInfo
- Publication number
- NO20041186L NO20041186L NO20041186A NO20041186A NO20041186L NO 20041186 L NO20041186 L NO 20041186L NO 20041186 A NO20041186 A NO 20041186A NO 20041186 A NO20041186 A NO 20041186A NO 20041186 L NO20041186 L NO 20041186L
- Authority
- NO
- Norway
- Prior art keywords
- diagnostic
- bombesin analog
- analog conjugates
- therapeutic somatostatin
- somatostatin
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title 1
- 108010056088 Somatostatin Proteins 0.000 title 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229960000553 somatostatin Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Percussion Or Vibration Massage (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32385101P | 2001-09-21 | 2001-09-21 | |
| PCT/US2002/030143 WO2003028527A2 (en) | 2001-09-21 | 2002-09-20 | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20041186L true NO20041186L (no) | 2004-05-05 |
Family
ID=23260992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20041186A NO20041186L (no) | 2001-09-21 | 2004-03-22 | Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7326685B2 (is) |
| EP (1) | EP1435826A4 (is) |
| JP (1) | JP4799820B2 (is) |
| KR (1) | KR20040047846A (is) |
| CN (1) | CN1589151A (is) |
| AU (1) | AU2002341792B2 (is) |
| BR (1) | BR0212897A (is) |
| CA (1) | CA2461099A1 (is) |
| IL (2) | IL160993A0 (is) |
| IS (1) | IS7189A (is) |
| MX (1) | MXPA04002621A (is) |
| NO (1) | NO20041186L (is) |
| NZ (1) | NZ532204A (is) |
| PL (1) | PL369336A1 (is) |
| WO (1) | WO2003028527A2 (is) |
| ZA (1) | ZA200402698B (is) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6721705B2 (en) * | 2000-02-04 | 2004-04-13 | Webley Systems, Inc. | Robust voice browser system and voice activated device controller |
| US7771727B2 (en) * | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| US8060626B2 (en) * | 2008-09-22 | 2011-11-15 | Sony Computer Entertainment America Llc. | Method for host selection based on discovered NAT type |
| US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US8709998B2 (en) * | 2003-04-22 | 2014-04-29 | Ipsen Pharma S.A.S. | Peptide vectors |
| US20050096256A1 (en) * | 2003-07-01 | 2005-05-05 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US20050255045A1 (en) * | 2004-05-13 | 2005-11-17 | Woltering Eugene A | Surgical marking composition and method |
| WO2005110485A1 (en) * | 2004-05-14 | 2005-11-24 | Interface Biologics Inc. | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
| CA2467321A1 (en) * | 2004-05-14 | 2005-11-14 | Paul J. Santerre | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
| US20060084085A1 (en) * | 2004-06-16 | 2006-04-20 | Sinclair David A | Methods and compositions for modulating Bax-mediated apoptosis |
| WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
| WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| CN102772358A (zh) * | 2005-06-16 | 2012-11-14 | 美瑞德生物工程公司 | 药物组合物及其用途 |
| US8735177B2 (en) | 2006-02-23 | 2014-05-27 | Adeka Corporation | Diagnostic marker |
| DE102006035083A1 (de) * | 2006-07-28 | 2008-01-31 | medac Gesellschaft für klinische Spezialgeräte mbH | Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel |
| ES2410207T3 (es) | 2006-10-16 | 2013-07-01 | The Salk Institute For Biological Studies | Antagonistas de la somatostatina selectivos para receptor(SSTR2) |
| US8691761B2 (en) | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
| WO2008051421A2 (en) * | 2006-10-20 | 2008-05-02 | Ipsen Pharma S.A.S. | Peptide-cytotoxic conjugates |
| EP2144887A4 (en) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER |
| CA2720989A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Methods for treating cancer |
| KR20100016385A (ko) * | 2007-04-10 | 2010-02-12 | 미리어드 파마슈티칼스, 인코포레이티드 | 뇌종양 치료방법 |
| NZ580867A (en) * | 2007-04-10 | 2011-02-25 | Myriad Pharmaceuticals Inc | Method of treating melanoma |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| WO2012112792A2 (en) | 2011-02-17 | 2012-08-23 | The Administrators Of The Tulane Educational Fund | Multicomponent compositions and their uses |
| US20160017058A1 (en) * | 2013-03-14 | 2016-01-21 | The California Institute For Biomedical Research | Bispecific antibodies and uses thereof |
| US12252534B2 (en) | 2016-02-04 | 2025-03-18 | The Scripps Research Institute | Humanized anti-CD3 antibodies, conjugates and uses thereof |
| AU2017217271C1 (en) | 2016-02-09 | 2021-08-05 | Cdrd Ventures Inc. | Somatostatin receptor antagonist compounds and methods of using the same |
| EP3433259B1 (en) | 2016-03-24 | 2021-06-30 | The Administrators of The Tulane Educational Fund | Conjugates of tacrolimus, their compositions, and their uses |
| EP3717019A4 (en) * | 2017-11-28 | 2021-09-22 | Board of Regents of the University of Nebraska | RADIOPHARMACEUTICALS AND METHOD OF USE THEREOF |
| EP3740494A4 (en) | 2018-02-02 | 2021-11-03 | Ripple Therapeutics Corporation | GLASS FORMULATIONS WITH STEROID DIMERS AND USES THEREOF |
| US20210000988A1 (en) * | 2018-03-15 | 2021-01-07 | Osaka University | Pharmaceutical composition containing 211at-labeled amino acid derivative, and method for producing said pharmaceutical composition |
| WO2020154815A1 (en) | 2019-02-01 | 2020-08-06 | Ripple Therapeutics Corporation | Crystalline forms of dexamethasone dimers and uses thereof |
| US12509469B2 (en) | 2019-08-07 | 2025-12-30 | Ripple Therapeutics Corporation | Compositions and methods for the treatment of pain and dependence disorders |
| CA3176134A1 (en) | 2020-05-01 | 2021-11-04 | Ripple Therapeutics Corporation | Heterodimer compositions and methods for the treatment of ocular disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4812590A (en) | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
| US5073541A (en) * | 1987-11-18 | 1991-12-17 | Administrators Of The Tulane Educational Fund | Treatment of small cell lung cancer with somatostatin analogs |
| US5753627A (en) | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
| US5633263A (en) | 1989-04-26 | 1997-05-27 | The Administrators Of The Tulane Educational Fund | Linear somatostatin analogs |
| ATE120374T1 (de) | 1989-07-20 | 1995-04-15 | Sandoz Ag | Markierte polypeptidderivate. |
| EP0450480B1 (en) * | 1990-04-06 | 1995-06-21 | The Administrators of The Tulane Educational Fund | Somatostatin Analogues |
| US5443815A (en) | 1991-11-27 | 1995-08-22 | Diatech, Inc. | Technetium-99m labeled peptides for imaging |
| US5411943A (en) | 1992-02-25 | 1995-05-02 | Biomeasure, Inc. | Hepatoma treatment with somatostatin analogs |
| US5620675A (en) * | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
| US5597894A (en) * | 1995-06-05 | 1997-01-28 | The Louisiana State University Medical Center Foundation | Multi-tyrosinated somatostatin analogs |
| US6051554A (en) | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US5770687A (en) | 1995-06-07 | 1998-06-23 | Peptor Limited | Comformationally constrained backbone cyclized somatostatin analogs |
| US5708135A (en) | 1995-09-29 | 1998-01-13 | Biomeasure Incorporated | Cyclic peptide analogs of somatostatin |
| US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| US6156725A (en) | 1996-08-16 | 2000-12-05 | National Institute Of Immunology | Drug for the treatment of cancer |
| WO1998047524A1 (en) | 1997-04-22 | 1998-10-29 | Curators Of The University Of Missouri | Gastrin receptor-avid peptide conjugates |
| AU4267700A (en) * | 2000-01-13 | 2001-07-19 | Academia Sinica | Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells |
| AU2002305845B2 (en) * | 2001-06-08 | 2006-03-30 | Ipsen Pharma S.A.S. | Somatostatin-dopamine chimeric analogs |
-
2002
- 2002-09-20 BR BR0212897-7A patent/BR0212897A/pt not_active IP Right Cessation
- 2002-09-20 AU AU2002341792A patent/AU2002341792B2/en not_active Ceased
- 2002-09-20 CN CNA028230817A patent/CN1589151A/zh active Pending
- 2002-09-20 KR KR10-2004-7004173A patent/KR20040047846A/ko not_active Ceased
- 2002-09-20 IL IL16099302A patent/IL160993A0/xx unknown
- 2002-09-20 EP EP02775944A patent/EP1435826A4/en not_active Withdrawn
- 2002-09-20 MX MXPA04002621A patent/MXPA04002621A/es active IP Right Grant
- 2002-09-20 PL PL02369336A patent/PL369336A1/xx not_active Application Discontinuation
- 2002-09-20 JP JP2003531872A patent/JP4799820B2/ja not_active Expired - Fee Related
- 2002-09-20 WO PCT/US2002/030143 patent/WO2003028527A2/en not_active Ceased
- 2002-09-20 US US10/490,326 patent/US7326685B2/en not_active Expired - Fee Related
- 2002-09-20 NZ NZ532204A patent/NZ532204A/en not_active IP Right Cessation
- 2002-09-20 CA CA002461099A patent/CA2461099A1/en not_active Abandoned
-
2004
- 2004-03-19 IS IS7189A patent/IS7189A/is unknown
- 2004-03-21 IL IL160993A patent/IL160993A/en not_active IP Right Cessation
- 2004-03-22 NO NO20041186A patent/NO20041186L/no not_active Application Discontinuation
- 2004-04-06 ZA ZA200402698A patent/ZA200402698B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040047846A (ko) | 2004-06-05 |
| JP4799820B2 (ja) | 2011-10-26 |
| CA2461099A1 (en) | 2003-04-10 |
| IL160993A (en) | 2011-04-28 |
| AU2002341792B2 (en) | 2007-09-06 |
| US20050070470A1 (en) | 2005-03-31 |
| JP2005505580A (ja) | 2005-02-24 |
| US7326685B2 (en) | 2008-02-05 |
| IS7189A (is) | 2004-03-19 |
| WO2003028527A3 (en) | 2003-10-30 |
| EP1435826A2 (en) | 2004-07-14 |
| WO2003028527A8 (en) | 2004-04-15 |
| NZ532204A (en) | 2006-04-28 |
| WO2003028527A2 (en) | 2003-04-10 |
| CN1589151A (zh) | 2005-03-02 |
| BR0212897A (pt) | 2004-08-24 |
| ZA200402698B (en) | 2005-04-25 |
| PL369336A1 (en) | 2005-04-18 |
| EP1435826A4 (en) | 2009-07-15 |
| MXPA04002621A (es) | 2004-07-08 |
| IL160993A0 (en) | 2004-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL160993A0 (en) | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof | |
| DK1404809T3 (da) | Forbedrede hudsubstitutter og anvendelser deraf | |
| DK2336167T3 (da) | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi | |
| NO20040246L (no) | TACI'er- og BR3-polypeptider og anvendelser derav | |
| DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
| NO20044192L (no) | 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater | |
| DE10295851T1 (de) | Dachfensterbaueinheit und Einzelteile | |
| NO20014560D0 (no) | Quinasoliner og terapautisk anvendelse derav | |
| DE60235204D1 (de) | Medizinische leitung und leitungsverbindungssystem | |
| AU2003228445A8 (en) | Tissue composites and uses thereof | |
| NO20030832L (no) | Kondenserte sykliske forbindelser og medisinsk anvendelse derav | |
| NO20034159D0 (no) | Östrogen-gestagen-kombinasjonspreparat og anvendelse derav | |
| EP1545599A4 (en) | IMMUNOGENIC COMPOSITIONS AND ITS DIAGNOSTIC AND THERAPEUTIC USES | |
| DE60209310D1 (de) | Aliphatishe Polyesterzusammensetzung und biegsame Erzeugnisse | |
| DE60205718D1 (de) | Flexibler wellschlauch und anschlussverfahren | |
| EP1572741A4 (en) | DIAGNOSTIC AND THERAPEUTIC AGENTS | |
| IS7577A (is) | Arómatísk súlfón og læknisfræðileg notkun þeirra | |
| AU2002303261A8 (en) | Gene brcc2 and diagnostic and therapeutic uses thereof | |
| IS2841B (is) | Samstæða hluta og lyfjasamsetningar | |
| NO20033123L (no) | Terapeutisk hinne dannende sammensetning og behandlingsplan derav | |
| DK1417189T3 (da) | Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf | |
| EP1462455A4 (en) | NOVEL PEPTIDES AND THEIR USES AS MEDICAMENTS | |
| DK1556382T3 (da) | 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf | |
| NO20042693L (no) | Kateterpreparat og anvendelser derav | |
| DK1456377T3 (da) | Syn3-sammensætninger og fremgangsmåder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |